Company Overview - Novavax has transitioned from a vertically integrated commercial organization focused on the launch of its COVID-19 vaccine, Nuvaxovid, to a model that emphasizes research and development (R&D) and diversified partnerships [3][4]. Business Model Evolution - From 2020 to 2022, the majority of Novavax's resources were dedicated to the development and introduction of Nuvaxovid, marking a singular focus on this product [4]. - In early 2023, the company began to evolve its business model to prioritize R&D and establish a broader range of partnerships [3]. Leadership and Presentation - The presentation at the Goldman Sachs 46th Annual Global Healthcare Conference featured key executives, including the CEO, CFO, and the head of R&D, indicating a strong leadership presence [1]. - The conference serves as a platform for Novavax to communicate its strategic direction and business evolution to potential investors and stakeholders [1].